<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030186</url>
  </required_header>
  <id_info>
    <org_study_id>C0701a/202/ON/US</org_study_id>
    <nct_id>NCT00030186</nct_id>
  </id_info>
  <brief_title>Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation</brief_title>
  <official_title>An Open-Label Study of CEP-701 in Patients With Refractory, Relapsed, or Poor Risk Acute Myeloid Leukemia Expressing FLT-3 Activating Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cephalon</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the response rate of patients with refractory,
      relapsed or poor risk AML expressing FLT-3 activating mutations, when administered CEP-701 at
      a dosage of 60 mg 2 times a day.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study of CEP-701 in patients with refractory, relapsed, or poor risk
      AML expressing FLT-3 activating mutations. Patients who meet eligibility criteria will be
      enrolled at a dosage of 60 mg orally 2 times a day for 28 days (1 cycle). Upon completion of
      cycle 1, the dosage may be increased to 80mg 2 times a day or decreased to 40 mg 2 times a
      day, dependent upon response to 60 mg dosage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">February 2003</completion_date>
  <primary_completion_date type="Actual">February 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Samples and/or bone marrow assessments for complete remission (CR), complete tumor clearance (CTC), or hematologic response (HR) from bone marrow</measure>
    <time_frame>56 days</time_frame>
    <description>Response rate of patients with refactory, relapsed, or poor risk acute myeloid leukemia (AML) expressing Fms-like tyrosine kinase 3 (FLT-3) activating mutations. CR is defined as presence of less than 5% myeloblasts in bone marrow with normalized peripheral blood cell counts. HR is defined as a 50% or more decrease in the absolute number of peripheral blast count or at least a 50% reduction in bone marrow blasts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days to response</measure>
    <time_frame>56 Days</time_frame>
    <description>Response as defined by CR, CTC, or HR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days to disease progression</measure>
    <time_frame>56 Days</time_frame>
    <description>Response as defined by CR, CTC, or HR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of FLT-3 phosphorylation inhibition in vivo</measure>
    <time_frame>56 Days</time_frame>
    <description>The degree of inhibition of FLT-3 autophosphorylation measured in ex vivo bioassay plasma samples</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Leukemia, Myeloid</condition>
  <arm_group>
    <arm_group_label>Cycle 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80mg dependent upon response to Cycle 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cycle 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40mg dependent upon response to Cycle 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEP-701 60mg</intervention_name>
    <description>60mg orally 2 times a day for 28 days</description>
    <arm_group_label>Cycle 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cep-701 80mg</intervention_name>
    <description>80mg 2 times a day, dependent upon response to cycle 1</description>
    <arm_group_label>Cycle 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cep-701 40mg</intervention_name>
    <description>40mg 2 times a day, dependent upon response to cycle 1</description>
    <arm_group_label>Cycle 2b</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  patient must have confirmed diagnosis of refractory or relapsed AML that expresses a
             FLT-3 mutation

          -  patient must have life expectancy of more than 2 months

          -  patient must be fully recovered from reversible side effects of previous therapy for
             cancer

        EXCLUSION CRITERIA:

          -  total bilirubin, ALT or AST greater than 2 times upper limit of normal

          -  patient &lt;65 years of age with estimated creatinine clearance less than 60 mL/min;
             patient &gt;65 years of age with serum creatinine &gt; 1.5 times the upper limit of normal
             (ULN)

          -  received any investigational drug within past 4 weeks

          -  GI disturbance/malabsorption that may affect absorption of CEP-701

          -  HIV positive

          -  received NSAID within prior 14 days

          -  has active infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2002</study_first_submitted>
  <study_first_submitted_qc>February 7, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2002</study_first_posted>
  <disposition_first_submitted>May 3, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>May 3, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 8, 2012</disposition_first_posted>
  <last_update_submitted>August 14, 2012</last_update_submitted>
  <last_update_submitted_qc>August 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>FLT-3 mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

